SUSAN GRAY: Open Payments
NPI 1306070701 · ORLANDO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$824 in 26 payments from 12 companies in 2025. Trend: 2023 $118 · 2024 $268 · 2025 $824
Food & beverage: $824
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 5 | $168 |
| Janssen Pharmaceuticals, Inc | 2 | $156 |
| Alkermes, Inc. | 5 | $103 |
| ABBVIE INC. | 1 | $102 |
| Teva Pharmaceuticals USA, Inc. | 3 | $67 |
| E.R. Squibb & Sons, L.L.C. | 3 | $55 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $31 |
| Stryker Corporation | 1 | $29 |
| Neurocrine BioSciences, Inc. | 1 | $25 |
Products named: INVEGA SUSTENNA, VRAYLAR, REXULTI, ABILIFY MAINTENA, LYBALVI, COBENFY, Auvelity, ARISTADA.
Industry payments across FL — which companies pay providers there.
